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The variance in glycemic control between different childhood diabetes centres is not fully 
understood. Although the ISPAD guidelines from 2014 recommended centre sizes of more than 150 
patients (1), it is not thoroughly investigated if glycemic control is associated with centre size (2-4). 
We have data from more than 500 childhood diabetes centres from seven different countries and 
thereby a unique opportunity to elaborate further on this association. Therefore, this study aims to 
investigate the relationship between centre size and glycemic control in children with type 1 
diabetes (T1D).  
 
Patient data have been described previously (5). Briefly, the population comprised children with 
T1D in the age group less than 18 years and diabetes duration of more than three months from  
seven high-income countries during 2013-2014: Austria, Denmark, England, Germany, Norway, 
Sweden and Wales. Data were anonymized and obtained from five national registries / audits on 
children with T1D (Austria and Germany use the same electronic health record, and England and 
Wales have a common National Pediatric Diabetes Audit, while Denmark, Norway and Sweden 
have national registries). Mean HbA1c was compared between groups after adjusting for gender, age 
(<6 years, 6 to <12 years, and 12 to 18 years), duration of diabetes (<2 years, 2 to <5 years, and ≥ 5 
years), minority status (yes/no) (HbA1c adj) before and after stratifying for treatment modality 
(insulin injection/pump). Centre size was defined as the number of diabetes patients reported to be 
cared for in a centre. Centre size groupings were: 1) < 20; 2) 20 - < 50; 3) 50 - < 100; 4) 100 - < 
200; 5) ≥ 200 patients.  
 
In total 54,494 children (48% females) with T1D across 504 centres in seven countries were 
included in the study.  The number of centres per country varied between 14 (Wales) and 219 
(Germany). Mean (standard deviation) for age was 12.5 (3.9) years, mean age at T1D onset was 7.5 
(4.0) years, and mean T1D duration was 5.0 (3.7) years. 21% of patients had minority status, which 
varied between 5% (Wales) and 28 % (Austria). 38.1% of patients were on pump treatment and the 
percentage varied between 25% (England) and 69% (Denmark). National coverage of T1D patients 
was above 95% in all countries, apart from Austria with about 80% data coverage. Included patients 
had 100% data coverage for all variables, gender, age, diabetes duration, minority status and HbA1c. 
Data on treatment modality were not available for 2428 patients (4.5%); of them 2130 were from 
England and 154 from Sweden. 
 
23.2% of centres had <50 patients (small centres) with T1D, which represented 4.9% of the total 
patient population. Most children (45.6%) were cared for in diabetes centres with a centre size 
between 100 and 200 patients. 30.2% of children were cared for in centres with more than 200 
patients, representing 12.3 % of all centres. The distribution of small and large centres in the seven 
countries varied. England and Sweden had few small centres (< 12%) while Austria, Germany and 
Norway had a higher percentage of small centres (>34%).  HbA1c adj was significantly higher in the 
centres with less than 50 patients compared with larger centres (P<0.001), while there was no 
difference in HbA1cadj with increasing centre size above 50 patients (figure). Stratification for 
treatment modality (insulin injection /pump) revealed that HbA1cadj was significantly higher in 
centres with less than 50 patients compared with centres with more than 50 patients, both in pen 
users (P< 0.001)  and pump users (P< 0.01). The influence of centre size was more pronounced in 
pen users, and pen users had higher HbA1cadj than pump users for all centre sizes (P<0.02) (figure). 
 
We conclude that the percentage of small and larger centres differed between countries, but in total 
the small centres (< 50 patients) comprised 23.2 percent of all diabetes centres in the seven 
countries. In all countries combined, childhood diabetes centres with less than 50 patients had 
higher HbA1c, This indicates that, where geographically possible, it may be beneficial to reduce the 
number of small centres and combine them into larger entities.  As small centres did better on pump 
than pen, small remote centres may benefit from encouraging pump use. Diabetes centres with more 
than 50 patients managed equally well, therefore centralizing to very high-volume diabetes centres 
may not necessarily be an advantage. Future research should focus on identifying reasons leading to 
differences in glycemic control in T1D patients cared for in small and large centres, e.g the lack or 
presence of an updated multidisciplinary diabetes team. 
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 Legend to figure 
HbA1c adj by centre size total and by treatment modality. Pen users had higher HbA1cadj than pump 
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